Jeffrey Wiezorek, SVP Clinical Development at Kite Pharma, Inc. (KITE), sold 8,280 shares at $44.56 ($370K) on 2016-03-15, disclosed to the SEC on 2016-03-17.
Open-market sale of $370k KITE by SVP Clinical Development. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $44.56 | 6,742 | $300K | 81.2% |
| 2 | $45.32 | 1,538 | $70K | 18.8% |
| Total | $44.70 avg | 8,280 | $370K | 100% |
| Filing → |
| KITE | SELL | 2017-07-06 | $1.0M | — | Filing → |
| KITE | SELL | 2017-03-02 | $1.4M | — | Filing → |
| KITE | SELL | 2017-02-06 | $77K | — | Filing → |